A tumor that secretes VASOACTIVE INTESTINAL PEPTIDE, a neuropeptide that causes VASODILATION; relaxation of smooth muscles; watery DIARRHEA; HYPOKALEMIA; and HYPOCHLORHYDRIA. Vipomas, derived from the pancreatic ISLET CELLS, generally are malignant and can secrete other hormones. In most cases, Vipomas are located in the PANCREAS but can be found in extrapancreatic sites.
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
Tumors or cancer of the LUNG.
Directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Conformity in fulfilling or following official, recognized, or institutional requirements, guidelines, recommendations, protocols, pathways, or other standards.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)

Pancreatic polypeptide hyperplasia causing watery diarrhea syndrome: a case report. (1/23)

Neuroendocrine tumours of the pancreas can secrete numerous peptides, leading to various recognizable clinical syndromes. The secretion of pancreatic polypeptide has been used as a marker for neuroendocrine tumours but is considered to be a biologically inert peptide. A 37-year-old woman had watery diarrhea syndrome from pancreatic polypeptide hyperplasia. Only 2 other reported cases in the literature have described pancreatic polypeptide hyperplasia; however, this is the first reported case in which the patient was successfully treated by surgical resection, with a 2-year follow-up. This report and review of the literature illustrate that pancreatic polypeptide hypersecretion may present as a clinical endocrinopathy.  (+info)

Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. (2/23)

Tumors of the endocrine pancreas are extremely rare, and molecular mechanisms leading to their development are not well understood. A candidate tumor suppressor gene, DPC4, located at 18q21, has recently been shown to be inactivated in half of pancreatic adenocarcinoma xenografts. The close anatomical relationship of the exocrine and endocrine pancreas prompted us to determine the role of DPC4 in the tumorigenesis of 25 pancreatic islet cell tumors (11 insulinomas, nine non-functioning endocrine carcinomas, three gastrinomas, two vipomas). A mutation screening of the highly conserved COOH-terminal domain of DPC4 (exons 8-11) was performed by single-strand conformational variant (SSCP) analysis and a PCR-based deletion assay. Five of nine (55%) non-functioning endocrine pancreatic carcinomas revealed either point mutations, small intragenic deletions or homozygous deletion of DPC4 sequences compared to none of the insulinomas, gastrinomas or vipomas. These results suggest that DPC4 is an important target gene promoting tumorigenesis of non-functioning neuroendocrine pancreatic carcinomas.  (+info)

Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. (3/23)

Our previous comparative genomic hybridization study on sporadic endocrine pancreatic tumors (EPTs) revealed frequent losses on chromosomes 11q, 3p, and 6q. The aim of this study was to evaluate the importance of 6q losses in the oncogenesis of sporadic EPTs and to narrow down the smallest regions of allelic deletion. A multimodal approach combining polymerase chain reaction-based allelotyping, double-target fluorescence in situ hybridization, and comparative genomic hybridization was used in a collection of 109 sporadic EPTs from 93 patients. Nine polymorphic microsatellite markers (6q13 to 6q25-q27) were investigated, demonstrating a loss of heterozygosity (LOH) in 62.2% of the patients. A LOH was significantly more common in tumors >2 cm in diameter than below this threshold as well as in malignant than in benign tumors. We were able to narrow down the smallest regions of allelic deletion at 6q22.1 (D6S262) and 6q23-q24 (D6S310-UTRN) with LOH-frequencies of 50.0% and 41.2 to 56.3%, respectively. Several promising tumor suppressor candidates are located in these regions. Additional fluorescence in situ hybridization analysis on 46 EPTs using three locus-specific probes (6q21, 6q22, and 6q27) as well as a centromere 6-specific probe revealed complete loss of chromosome 6 especially in metastatic disease. We conclude that the two hot spots found on 6q may harbor putative tumor suppressor genes involved not only in the oncogenesis but maybe also in the malignant and metastatic progression of sporadic EPTs.  (+info)

Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. (4/23)

Few studies have concerned the rare functioning endocrine pancreatic tumors associated with multiple endocrine neoplasia type 1 (MEN 1). When sporadic, these tumors have a poor prognosis. AIM: To analyze the frequency, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas and somatostatinomas recorded in the GTE (Groupe des Tumeurs Endocrines) registry. METHODS: Records of the patients whose GTE registry codes included glucagonoma, VIPoma or somatostatinoma were reviewed. The diagnosis was confirmed when there were clinical signs of a functioning tumor and/or when blood levels of the peptide were higher than twice the upper limit of normal. RESULTS: Among 580 patients with MEN 1, duodeno-pancreatic involvement was present in 307 (52.9%). Five (1.6%) had a glucagonoma, 3 (0.98%) a VIPoma and 2 (0.65%) a somatostatinoma. A clinical syndrome was present in 1 patient with glucagonoma, in the 3 with VIPomas and in 1 with somatostatinoma. Tumor size was greater than 3 cm more often for these rare tumours (67%) than in patients with other type of duodeno-pancreatic involvement (28%) (P=0.02) and visceral metastases were more frequent (40% vs 15%; P=0.056). Ten-year survival of patients with glucagonomas, VIPomas or somatostatinomas (53.8%; CI95%: 15.5-92.1) was poorer than that of patients with insulinomas (91.4%; CI95%: 83.399.5; P=0.01) or gastrinomas (81.7%; CI95%: 74.9-88.5; P=0.20) and close to that of patients with non-functioning tumors (62.2%, CI95%: 41.0-83.9; NS). CONCLUSION: Glucagonomas, VIPomas and somatostatinomas, especially the functioning type, are very rare in patients with MEN 1. Prognosis is poor, probably because of large tumor size and high rate of metastasis. Survival is similar to that in patients with non-functioning tumors.  (+info)

BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. (5/23)

The BRAF gene, one of the human isoforms of RAF, is activated by ras, leading to cooperative effects in cells responsive to growth factor signals. We studied the frequency of BRAF and k-ras-2 mutations in primary neuroendocrine gastroenteropancreatic (GEP) tumors. Mutation analysis of the BRAF and k-ras-2 genes was performed in 40 primary neuroendocrine tumors of the GEP system. The expression of extracellular signaling-related kinase (ERK) 1/2, an important downstream point of convergence in the ras-RAF-mitogen-activated protein-ERK pathway was analyzed immunohistochemically. We detected one 1796 T-->A BRAF mutation that led to a substitution of valine by glutamic acid at position 599 (V599E) in 40 primary neuroendocrine GEP tumors (3%). We failed to detect specific mutation of the k-ras-2 gene. We identified constitutively activated ERK in almost all neuroendocrine tumor tissues tested irrespective of BRAF mutation or localization or functional activity. These results suggest that BRAF mutations do not have a role in tumorigenesis of neuroendocrine tumors. Nevertheless, activation of the RAF/mitogen-activated protein kinase pathway might have a causative role in the development of neuroendocrine tumors, independent of BRAF or k-ras-2 mutation.  (+info)

Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. (6/23)

OBJECTIVE: To evaluate the outcome of an aggressive surgical approach for duodenopancreatic neuroendocrine tumors (PETs) associated with multiple endocrine neoplasia type 1 (MEN1). SUMMARY BACKGROUND DATA: The management of PETs is still controversial in the setting of the autosomal dominant inherited MEN1 syndrome. METHODS: MEN1 patients that had either biochemical evidence of functioning PETs or visualized nonfunctioning PETs larger than 1 cm in size on imaging were operated. Since 1997, patients were followed annually by biochemical testing and imaging studies. RESULTS: Twenty-six genetically confirmed MEN1 patients underwent duodenopancreatic resection for functioning (n = 17) or nonfunctioning (n = 9) PETs. Ten (38%) patients had malignant PETs as characterized by the presence of lymph node (10 patients) and/or distant metastases (2 patients). The surgical approach was selected based on the type, location, and size of PETs. Four Zollinger-Ellison syndrome (ZES) patients required pylorus preserving pancreaticoduodenectomy (PPPD) as initial or redo procedure, 20 patients underwent other duodenopancreatic resections, and 2 patients had simple enucleations of PETs. After median 83 months (range, 5-241 months), 24 patients were alive and 2 patients died of an unrelated cause. All patients with insulinoma or vipoma and 7 of 11 patients with ZES were biochemically cured, including the ZES patients who underwent PPPD. However, 19 of 26 (73%) patients developed new small PETs (<1 cm) in the pancreatic remnant, but no patient had yet detectable metastases on imaging. CONCLUSIONS: Early and aggressive surgery of PETs in MEN1 patients prevents the development of liver metastases, which are the most life-threatening determinant. PPPD might be the procedure of choice for MEN1-ZES, which has to be proven in large scale studies.  (+info)

Watery diarrhea, hypokalemia and achlorhydria syndrome due to an adrenal pheochromocytoma. (7/23)

Watery diarrhea, hypokalemia and achlorhydria (WDHA) syndrome caused by vasoactive intestinal polypeptide (VIP) -producing tumor only rarely occurs in patients with nonpancreatic disease. A 49-year-old woman was referred for evaluation of a right adrenal tumor incidentally diagnosed by abdominal ultrasound during the investigation of chronic watery diarrhea. Laboratory findings showed hypokalemia and excessive production of VIP and catecholamines. After surgical resection of the tumor, diarrhea subsided and both electrolytes and affected hormone levels normalized. Immunohistochemical examination confirmed a diagnosis of pheochromocytoma, which contained VIP-positive ganglion-like cells. We herein present the clinical and histogenetic implications of this rare clinical entity, with literature review.  (+info)

Population-based study of islet cell carcinoma. (8/23)

BACKGROUND: We examine the epidemiology, natural history, and prognostic factors that affect the duration of survival for islet cell carcinoma by using population-based registries. METHODS: The Surveillance, Epidemiology, and End Results (SEER) Program database (1973-2003 release, April 2006) was used to identify cases of islet cell carcinoma by histology codes and tumor site. RESULTS: A total of 1310 (619 women and 691 men) cases with a median age of 59 years were identified. The annual age-adjusted incidence in the periods covered by SEER 9 (1973-1991), SEER 13 (1992-1999), and SEER 17 (2000-2003) were .16, .14, and .12 per 100,000, respectively. The estimated 28-year limited duration prevalence on January 1, 2003, in the United States was 2705 cases. Classified by SEER stage, localized, regional, and distant stages corresponded to 14%, 23%, and 54% of cases. The median survival was 38 months. By stage, median survival for patients with localized, regional, and distant disease were 124 (95% CI, 80-168) months, 70 (95% CI, 54-86) months, and 23 (95% CI, 20-26) months, respectively. By multivariate Cox proportional modeling, stage (P < .001), primary tumor location (P = .04), and age at diagnosis (P < .001) were found to be significant predictors of survival. CONCLUSIONS: Islet cell carcinomas account for approximately 1.3% of cancers arising in the pancreas. Most patients have advanced disease at the time of diagnosis. Despite the disease's reputation of being indolent, survival of patients with advanced disease remains only 2 years. Development of novel therapeutic approaches is needed.  (+info)

A vipoma, also known as a verner morrison syndrome or a non-insulin-secreting pancreatic tumor, is a rare medical condition characterized by the excessive production and secretion of vasoactive intestinal peptides (VIP) from a functional neuroendocrine tumor in the pancreas. This leads to a series of symptoms known as watery diarrhea, hypokalemia, and acidosis (WDHA) syndrome due to the effects of VIP on the gastrointestinal system. Symptoms include severe watery diarrhea, dehydration, electrolyte imbalances, and low blood pressure. Treatment typically involves surgical removal of the tumor, along with supportive care to manage symptoms and correct electrolyte abnormalities.

A carcinoid tumor is a type of slow-growing neuroendocrine tumor that usually originates in the digestive tract, particularly in the small intestine. These tumors can also arise in other areas such as the lungs, appendix, and rarely in other organs. Carcinoid tumors develop from cells of the diffuse endocrine system (also known as the neuroendocrine system) that are capable of producing hormones or biologically active amines.

Carcinoid tumors can produce and release various hormones and bioactive substances, such as serotonin, histamine, bradykinins, prostaglandins, and tachykinins, which can lead to a variety of symptoms. The most common syndrome associated with carcinoid tumors is the carcinoid syndrome, characterized by flushing, diarrhea, abdominal cramping, and wheezing or difficulty breathing.

Carcinoid tumors are typically classified as functional or nonfunctional based on whether they produce and secrete hormones that cause symptoms. Functional carcinoid tumors account for approximately 30% of cases and can lead to the development of carcinoid syndrome, while nonfunctional tumors do not produce significant amounts of hormones and are often asymptomatic until they grow large enough to cause local or distant complications.

Treatment options for carcinoid tumors depend on the location, size, and extent of the tumor, as well as whether it is functional or nonfunctional. Treatment may include surgery, medications (such as somatostatin analogs, chemotherapy, or targeted therapies), and radiation therapy. Regular follow-up with imaging studies and biochemical tests is essential to monitor for recurrence and assess treatment response.

Neuroendocrine tumors (NETs) are a diverse group of neoplasms that arise from cells of the neuroendocrine system, which is composed of dispersed neuroendocrine cells throughout the body, often in close association with nerves and blood vessels. These cells have the ability to produce and secrete hormones or hormone-like substances in response to various stimuli. NETs can occur in a variety of organs, including the lungs, pancreas, small intestine, colon, rectum, stomach, and thyroid gland, as well as in some less common sites such as the thymus, adrenal glands, and nervous system.

NETs can be functional or nonfunctional, depending on whether they produce and secrete hormones or hormone-like substances that cause specific symptoms related to hormonal excess. Functional NETs may give rise to a variety of clinical syndromes, such as carcinoid syndrome, Zollinger-Ellison syndrome, pancreatic neuroendocrine tumor syndrome (also known as Verner-Morrison or WDHA syndrome), and others. Nonfunctional NETs are more likely to present with symptoms related to the size and location of the tumor, such as abdominal pain, intestinal obstruction, or bleeding.

The diagnosis of NETs typically involves a combination of imaging studies, biochemical tests (e.g., measurement of serum hormone levels), and histopathological examination of tissue samples obtained through biopsy or surgical resection. Treatment options depend on the type, location, stage, and grade of the tumor, as well as the presence or absence of functional symptoms. They may include surgery, radiation therapy, chemotherapy, targeted therapy, and/or peptide receptor radionuclide therapy (PRRT).

Lung neoplasms refer to abnormal growths or tumors in the lung tissue. These tumors can be benign (non-cancerous) or malignant (cancerous). Malignant lung neoplasms are further classified into two main types: small cell lung carcinoma and non-small cell lung carcinoma. Lung neoplasms can cause symptoms such as cough, chest pain, shortness of breath, and weight loss. They are often caused by smoking or exposure to secondhand smoke, but can also occur due to genetic factors, radiation exposure, and other environmental carcinogens. Early detection and treatment of lung neoplasms is crucial for improving outcomes and survival rates.

Practice guidelines, also known as clinical practice guidelines, are systematically developed statements that aim to assist healthcare professionals and patients in making informed decisions about appropriate health care for specific clinical circumstances. They are based on a thorough evaluation of the available scientific evidence, consensus of expert opinion, and consideration of patient preferences. Practice guidelines can cover a wide range of topics, including diagnosis, management, prevention, and treatment options for various medical conditions. They are intended to improve the quality and consistency of care, reduce unnecessary variations in practice, and promote evidence-based medicine. However, they should not replace clinical judgment or individualized patient care.

Neoplasm staging is a systematic process used in medicine to describe the extent of spread of a cancer, including the size and location of the original (primary) tumor and whether it has metastasized (spread) to other parts of the body. The most widely accepted system for this purpose is the TNM classification system developed by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC).

In this system, T stands for tumor, and it describes the size and extent of the primary tumor. N stands for nodes, and it indicates whether the cancer has spread to nearby lymph nodes. M stands for metastasis, and it shows whether the cancer has spread to distant parts of the body.

Each letter is followed by a number that provides more details about the extent of the disease. For example, a T1N0M0 cancer means that the primary tumor is small and has not spread to nearby lymph nodes or distant sites. The higher the numbers, the more advanced the cancer.

Staging helps doctors determine the most appropriate treatment for each patient and estimate the patient's prognosis. It is an essential tool for communication among members of the healthcare team and for comparing outcomes of treatments in clinical trials.

Guideline adherence, in the context of medicine, refers to the extent to which healthcare professionals follow established clinical practice guidelines or recommendations in their daily practice. These guidelines are systematically developed statements designed to assist practitioners and patient decisions about appropriate health care for specific clinical circumstances. Adherence to evidence-based guidelines can help improve the quality of care, reduce unnecessary variations in practice, and promote optimal patient outcomes. Factors that may influence guideline adherence include clinician awareness, familiarity, agreement, self-efficacy, outcome expectancy, and the complexity of the recommendation.

Carcinoma, neuroendocrine is a type of cancer that arises from the neuroendocrine cells, which are specialized cells that have both nerve and hormone-producing functions. These cells are found throughout the body, but neuroendocrine tumors (NETs) most commonly occur in the lungs, gastrointestinal tract, pancreas, and thyroid gland.

Neuroendocrine carcinomas can be classified as well-differentiated or poorly differentiated based on how closely they resemble normal neuroendocrine cells under a microscope. Well-differentiated tumors tend to grow more slowly and are less aggressive than poorly differentiated tumors.

Neuroendocrine carcinomas can produce and release hormones and other substances that can cause a variety of symptoms, such as flushing, diarrhea, wheezing, and heart palpitations. Treatment for neuroendocrine carcinoma depends on the location and extent of the tumor, as well as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.

A VIPoma or vipoma (/vɪˈpoʊmə/) is a rare endocrine tumor that overproduces vasoactive intestinal peptide (thus VIP + -oma). ... "VIPoma , Genetic and Rare Diseases Information Center (GARD) - an NCATS Program". rarediseases.info.nih.gov. Retrieved 2018-04- ... Sandhu S, Jialal I. "ViPoma". National Center for Biotechnology Information, U.S. National Library of Medicine. Retrieved 5 ... "VIPoma" at Dorland's Medical Dictionary Mansour JC, Chen H (Jul 2004). "Pancreatic endocrine tumors". J Surg Res. 120 (1): 139- ...
VIP is overproduced in VIPoma. In addition to VIPoma, VIP has a role in osteoarthritis (OA). While there is existing conflict ...
"eMedicine - VIPoma : Article by Robert J Ferry, Jr, MD". Archived from the original on 16 August 2007. Retrieved 2007-09-22. ... VIPoma Carcinoid tumor Welbourn RB (1977). "Current status of the apudomas". Ann. Surg. 185 (1): 1-12. doi:10.1097/00000658- ...
Williams was diagnosed with VIPoma in 2018 and, after treatment, became an ambassador for Pancreatic Cancer UK. 2001: Lucky ...
... such as a VIPoma, an insulinoma, or a pheochromocytoma, are typically not referred to as adenocarcinomas but rather are often ...
This complex, referred to as the watery diarrhea, hypokalemia and achlorhydria syndrome (VIPoma) has been ascribed to ...
... lung cancer Endocrine pancreatic tumors Non-functioning endocrine pancreatic tumors Insulinoma Gastrinoma Glucagonoma VIPoma ...
... vipoma MeSH C04.557.470.200.025.390 - carcinoma, renal cell MeSH C04.557.470.200.025.415 - carcinoma, signet ring cell MeSH ... vipoma MeSH C04.557.465.625.650.510 - melanoma MeSH C04.557.465.625.650.510.385 - hutchinson's melanotic freckle MeSH C04.557. ... vipoma MeSH C04.588.322.421.750 - carcinoma, pancreatic ductal MeSH C04.588.322.455 - ovarian neoplasms MeSH C04.588.322.455. ... vipoma MeSH C04.588.274.761.750 - carcinoma, pancreatic ductal MeSH C04.588.274.780 - peritoneal neoplasms MeSH C04.588.322.078 ...
... access steal syndrome Vasoplegic syndrome Vestibulocerebellar syndrome Vici syndrome Villaret's syndrome VIP syndrome VIPoma ...
... vipoma MeSH C19.344.421.750 - carcinoma, pancreatic ductal MeSH C19.344.609.145 - acth-secreting pituitary adenoma MeSH C19.344 ...
... vipoma MeSH C06.301.761.750 - carcinoma, pancreatic ductal MeSH C06.405.117.102 - barrett esophagus MeSH C06.405.117.119 - ... vipoma MeSH C06.689.667.625 - carcinoma, pancreatic ductal MeSH C06.689.750.650 - pancreatitis, acute necrotizing MeSH C06.689. ...
Mixed acinar-endocrine carcinoma Mixed ductal-endocrine carcinoma M8155/1 Vipoma, NOS (M8155/3) Vipoma, malignant M8156/1 ...
... and high blood glucose levels VIPoma, producing excessive vasoactive intestinal peptide, which may cause profound chronic ...
Vipoma (M8160/3) Cholangiocarcinoma (M8170/3) Hepatocellular carcinoma, NOS (M8200/3) Adenoid cystic carcinoma (M8312/3) Renal ...
... dysfunction progressive familial Viljoen-Kallis-Voges syndrome Viljoen-Smart syndrome Viljoen-Winship syndrome Vipoma Viral ...
A VIPoma or vipoma (/vɪˈpoʊmə/) is a rare endocrine tumor that overproduces vasoactive intestinal peptide (thus VIP + -oma). ... "VIPoma , Genetic and Rare Diseases Information Center (GARD) - an NCATS Program". rarediseases.info.nih.gov. Retrieved 2018-04- ... Sandhu S, Jialal I. "ViPoma". National Center for Biotechnology Information, U.S. National Library of Medicine. Retrieved 5 ... "VIPoma" at Dorlands Medical Dictionary Mansour JC, Chen H (Jul 2004). "Pancreatic endocrine tumors". J Surg Res. 120 (1): 139- ...
This flashcard is about vipoma. Learn medical terms with our smart flashcards. ...
Vipoma (Verner-Morrison syndrome, pancreatic cholera, WDHA syndrome - for watery diarrhea, hypokalemia, and achlorhydria) is ... Order fasting serum VIP for patients suspected of having vipoma (presenting with otherwise unexplained high volume secretory ... diarrhea, supported by low osmotic gap in a stool specimen). In vipoma, fasting serum VIP concentrations are usually greater ... fasting VIP concentration in the presence of secretory diarrhea should be repeated to establish the diagnosis of vipoma. ...
VIPoma. Recommendations for treatment of NETs that secrete vasoactive intestinal peptide (VIPomas) include the following:. * ... What are the guidelines on the treatment of pancreatic VIPoma?. What are the NCCN guidelines on the treatment of metastatic ...
Vipoma - Etiology, pathophysiology, symptoms, signs, diagnosis & prognosis from the MSD Manuals - Medical Professional Version ... Symptoms and Signs of Vipoma The major symptoms of vipoma are prolonged massive watery diarrhea (fasting stool volume > 750 to ... A vipoma is a non-beta pancreatic islet cell tumor secreting vasoactive intestinal peptide (VIP), resulting in a syndrome of ... In about 6% of patients, vipoma occurs as part of multiple endocrine neoplasia Overview of Multiple Endocrine Neoplasias (MEN) ...
Joyce, D. L., Hong, K., Fishman, E. K., Wisell, J., & Pawlik, T. M. (2008). Multi-visceral resection of pancreatic VIPoma in a ... Joyce, DL, Hong, K, Fishman, EK, Wisell, J & Pawlik, TM 2008, Multi-visceral resection of pancreatic VIPoma in a patient with ... Multi-visceral resection of pancreatic VIPoma in a patient with sinistral portal hypertension. In: World Journal of Surgical ... Multi-visceral resection of pancreatic VIPoma in a patient with sinistral portal hypertension. / Joyce, David L.; Hong, Kelvin ...
... of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma. ...
Clinical manifestations of VIPoma. *Adrenal glands *Aldosterone / Renin / Angiotensin. *Adrenocorticotropic hormone (ACTH) / ...
VIPoma:. *Weight loss. *Abdominal cramps or pain. *Watery diarrhea. *Dehydration symptoms. *Symptoms related to low potassium ...
VIPoma. Recommendations for treatment of NETs that secrete vasoactive intestinal peptide (VIPomas) include the following:. * ... What are the guidelines on the treatment of pancreatic VIPoma?. What are the NCCN guidelines on the treatment of metastatic ...
VIPoma: A form of pancreatic tumor that secretes vasoactive intestinal polypeptide (VIP), which causes severe diarrhea and ...
Carcinoid tumor or vasoactive intestinal peptide tumor (VIPoma). * Acquired immunodeficiency syndrome (AIDS) ...
... the patients record must document an abnormal octreotide scan leading to suspicion of VIPoma. ... the patients record must document abnormal findings leading to suspicion of VIPoma. ... the medical record must document that the patients diagnosis is VIPoma. ...
Vasoactive intestinal polypeptide secreting tumor (VIPoma) (~2%) - Verner-Morrison syndrome *Watery diarrhea, hypokalemia, ...
Table 4. Adverse Events Occurring in ≥ 15% of Carcinoid Tumor and VIPoma Patients in Study 1 Number (%) of Subjects With AEs (n ... VIPoma: VIP (plasma vasoactive intestinal peptide) baseline and periodic total and/or free T4 measurements should be performed ... carcinoid tumor and VIPoma patients should continue to receive Sandostatin Injection subcutaneously for at least 2 weeks in the ...
Most common location of glucagonoma and VIPoma in pancreas Distal * Endocrine tumor causing watery diarrhea, hypokalemia, ...
In cases of VIPoma and colonic pseudo-obstruction, which cause marked watery diarrhea, K secretion into the stool is abnormally ...
VIPoma) Diagnosis]: ... A diagnosis of advanced metastatic carcinoid tumor or VIPoma; ...
The VIPoma syndrome. *When is thrombolytic therapy indicated in PE. *Which ischemic stroke patients need a TEE? ...
Phenotype data for mouse gene Sepsecs. Discover Sepsecss significant phenotypes, expression, images, histopathology and more. Data for gene Sepsecs is all freely available for download.
Various endocrine tumors produce secretagogues, including vipomas Vipoma A vipoma is a non-beta pancreatic islet cell tumor ... vipoma, mastocytosis), chronic abdominal pain (irritable bowel, inflammatory bowel disease, gastrinoma), and GI bleeding ( ...
A knowledge graph of biological entities such as genes, gene functions, diseases, phenotypes and chemicals. Embeddings are generated with Walking RDF and OWL method ...
VIPoma; Pancreatic islet alpha cell tumor; Gastrinomas/Zollinger-Ellison syndrome is often combined with treatment with proton ...
VIPoma VIPoma A VIPoma is a rare neuroendocrine tumor arising primarily in the pancreas that releases large amounts of ...
Erika+2211969 Shared Gastrointestinal - 64 Picmonics
Post-cholecystectomy diarrhea is a common condition after gallbladder surgery. Therefore, if the onset of diarrheal attack started after cholecystectomy, think of post-cholecystectomy syndrome.. This condition is common and can affect up to 20% of people after gallbladder removal. Random attacks of diarrhea can happen because your colon cannot handle excess bile acids. (reference). A characteristic feature of this type of diarrhea is a severe urge to poop. It may become severe when soiling accidents occur (secondary bile acid diarrhea).. The diarrhea attacks are related to the ingestion of fatty foods. Post-cholecystectomy diarrhea can last anytime between a few weeks to several years.. Consult your doctor if you believe that random diarrhea is related to cholecystectomy. ...
Vipoma Viprynium use Pyrvinium Compounds Viral Accessory Proteins use Viral Regulatory and Accessory Proteins ...
Chromogranin A is a secretory protein, composed of 439 amino acids, found in the large dense-core vesicles of the neuroendocrine cells. It belongs to the family of granins that includes chromogranin B, chromogranin C, and secretogranin II.
Vipoma Viprynium use Pyrvinium Compounds Viral Accessory Proteins use Viral Regulatory and Accessory Proteins ...
  • They can be functional, exhibiting a hormonal hypersecretion syndrome, but can be non-functional presenting with non-specific symptoms and include insulinoma, glucagonoma, VIPoma, somatostatinoma (SSoma), PPoma and Zollinger-Ellison syndrome (ZES, or gastrinoma) and other ectopic hormone producing tumors (such as GRFoma) (see these terms). (findzebra.com)
  • A VIPoma or vipoma (/vɪˈpoʊmə/) is a rare endocrine tumor that overproduces vasoactive intestinal peptide (thus VIP + -oma). (wikipedia.org)
  • A vipoma is a non-beta pancreatic islet cell tumor secreting vasoactive intestinal peptide (VIP), resulting in a syndrome of watery diarrhea, hypokalemia, and achlorhydria (WDHA syndrome). (msdmanuals.com)
  • During a ct scan and pet scan for a vipoma -pancreatic tumor, my left lung showed a growth, I also have sleep apnea. (candacesilversstudios.com)
  • Vipoma (Verner-Morrison syndrome, pancreatic cholera, WDHA syndrome - for watery diarrhea, hypokalemia, and achlorhydria) is one of several rare types of functioning pancreatic neuroendocrine tumors (NETs) and accounts for 2-4% of all pancreatic NETs. (cancertherapyadvisor.com)
  • A three-dimensional (3-D) pancreas protocol computed tomography scan revealed an 18 × 12 cm pancreatic VIPoma abutting the liver, stomach, spleen, left adrenal, colon that also invaded the distal duodenum - proximal jejunum at the ligament of Treitz in association with sinistral portal hypertension. (elsevierpure.com)
  • Aggressive resection of patients with advanced VIPoma neuroendocrine tumors has rarely been reported. (elsevierpure.com)
  • Order fasting serum VIP for patients suspected of having vipoma (presenting with otherwise unexplained high volume secretory diarrhea, supported by low osmotic gap in a stool specimen). (cancertherapyadvisor.com)
  • A single elevated fasting VIP concentration in the presence of secretory diarrhea should be repeated to establish the diagnosis of vipoma. (cancertherapyadvisor.com)
  • Diagnosis of vipoma requires demonstration of secretory diarrhea (stool osmolality is close to plasma osmolality, and twice the sum of sodium and potassium concentration in the stool accounts for all measured stool osmolality). (msdmanuals.com)
  • Although false ves being reported, alzheimers disease chromosome codes for non-numerical data may be justied to make sure responses are consistent with the vipoma syndrome. (familytreecounseling.com)
  • Following preoperative proximal splenic artery embolization, the patient with underwent successful en bloc resection of the locally advanced VIPoma in conjunction with a diaphragmatic resection, total gastrectomy, splenectomy, left adrenalectomy, as well as small and large bowel resection. (elsevierpure.com)
  • A VIPoma or vipoma (/vɪˈpoʊmə/) is a rare endocrine tumor that overproduces vasoactive intestinal peptide (thus VIP + -oma). (wikipedia.org)
  • VIPoma causes cells in the pancreas to produce a high level of a hormone called vasoactive intestinal peptide (VIP). (medlineplus.gov)
  • A doctor bases the diagnosis of vipoma on the person's diarrhea symptoms and finding elevated levels of vasoactive intestinal peptide (VIP) in the blood. (msdmanuals.com)
  • We report a patient with MEN-I who exhibited rapid growth of multiple collagenomas after pancreatic enucleation of a vasoactive intestinal peptide-secreting tumor (VIPoma) and excision of multiple pancreatic masses. (nih.gov)
  • Pancreatic neuroendocrine tumors can overproduce hormones such as insulin (insulinoma), gastrin (gastrinoma), glucagon (glucagonoma), or vasoactive peptide protein (VIPoma). (news-medical.net)
  • Vipoma is an acronym which stands for vasoactive intestinal polypeptide (VIP), which is otherwise known as Verner Morrison syndrome. (cancerwall.com)
  • VIPoma - the over-production of vasoactive intestinal peptide by a VIPoma can cause severe watery diarrhoea and fatigue, muscle weakness and palpitations due to a low blood potassium level. (yourhormones.info)
  • The primary pathology was tumour (benign insulinoma 3, malignant vipoma 3, mixed endocrine tumours 3, cystadenoma 1 and cystadenocarcinoma 1), pancreatitis (acute 5, chronic 2) and trauma (2). (ox.ac.uk)
  • We encountered a case of pancreatic VIPoma in MEN Type I. A 49 year old man was referred from his local hospital presenting with a sudden onset of an explosive watery diarrhea of 3 months duration. (e-enm.org)
  • This is the first report of pancreatic VIPoma in MEN type I in Korea. (e-enm.org)
  • VIPoma is a very rare cancer that usually grows from cells in the pancreas called islet cells. (medlineplus.gov)
  • 9. Cure of intractable watery diarrhoea by excision of a vipoma. (nih.gov)
  • Despite of continuous octreotide therapy, interferon and two courses of combination chemotherapy, the hepatic metastases failed to regress and the patient died 10 months after the diagnosis of a metastatic VIPoma. (e-enm.org)
  • Some people seem to respond to a combination chemo called capecitabine and temozolomide but there is no report that it totally cured people of VIPoma. (wikipedia.org)
  • Each year, only about 1 in 1 million people are diagnosed with a VIPoma. (medlineplus.gov)